Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

The conversation is about whether a doctor is needed for injections of a product called SCUBE3 for hair loss. No specific treatments were discussed.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The user is experiencing increased hair shedding after 7 months of using a topical solution and is considering switching to oral treatment. They are concerned about thinning hair around the corners and temples.

A 40-year-old user shared their hair loss treatment progress since October 2023, using exosome treatment, minoxidil, finasteride, and microneedling. They started slacking on microneedling in February after stopping minoxidil.

A user shared their 6-month progress using daily oral dutasteride and minoxidil, along with monthly mesotherapy including zinc, dutasteride, minoxidil, biotin, and panthenol, reporting no noticeable side effects. Encouragement was given to continue despite potential hair shedding.

The user has been using kx826 for 10 months and topical minoxidil for 2 years, reporting slow but undeniable progress in hair regrowth. They experienced side effects from finasteride and do not use it.

The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

A 27-year-old male is using a minoxidil and finasteride spray for hairline recession and is considering other treatments like oral minoxidil, exosomes, PRP, or a hair transplant. Suggestions include microneedling, possibly with tretinoin, while another user suggests the hairline is fine and mentions body dysmorphia.

The conversation discusses the use of finasteride for hair loss, comparing every day (ED) versus every other day (EOD) dosing. It suggests that both dosing schedules can be effective, but individual tolerance may vary.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

After over a year of treatment with daily oral dutasteride and minoxidil, plus injected dutasteride every 6 months, the user is happy with the increased thickness of their hair and improved self-esteem, although scalp visibility remains. They encourage others to follow similar treatments for long-term hair maintenance.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

The conversation discusses the potential effectiveness of a Sult1a1 enzyme booster in enhancing the results of minoxidil for hair loss. Users express interest in the booster, hoping it will improve the effectiveness of oral minoxidil, especially for those who struggle with topical application.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

A user shared their 5-month hair loss treatment progress, using 1mg finasteride, daily GHK-CU injections, keratin/biotin/MSM supplements, Pura D’Or shampoo and conditioner, Ayurvedic oil, ketoconazole thrice weekly, and weekly microneedling with topical GHK-CU. The post includes progress pictures.

A user is considering using a 0.025% topical finasteride solution with DMSO to enhance absorption but is unsure about its effectiveness and safety. Other users express concerns about DMSO's properties and potential effects on the scalp.